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Abstract 
 
Objective: Cognitive-behavioral therapy (CBT) aims to help patients establish new behaviors 
that will be maintained and adapted to the demands of new situations. The long-term outcomes 
are therefore crucial in testing the durability of CBT. 
Method: A two-year follow-up assessment was undertaken on a subsample of n = 146 PD/AG 
patients from a multicenter randomized controlled trial. Treatment consisted of two variations of 
CBT: exposure in situ in the presence of the therapist (T+) or on their own following therapist 
preparation (T-).  
Results: Both variations of CBT had high response rates and, overall, maintained the level of 
symptomatology observed at post-treatment with high levels of clinical significance. Effect sizes 
24 months following treatment were somewhat lower than at the 6-month follow up. Once 
patients reached responder status, they generally tended to remain responders at subsequent 
assessments. Differences were observed for patients that obtained additional treatment during the 
follow-up period. Expert opinion and subjective appraisal of treatment outcome differed. No 
robust baseline predictors of 2-year outcome were observed.  
Conclusion: Most patients maintain clinically meaningful changes two years following treatment 
across multiple outcome measures. Approximately 1/3 of patients continued to experience 
meaningful residual problems.    
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Long-Term Response to CBT for Panic Disorder with Agoraphobia: A Two-Year Follow-Up 
Study 
 
Cognitive Behavioral Treatment (CBT) operates under the premise that patients learn new 
ways of responding to the internal and situational stimuli that combine to create impairment. 
Implicit is the assumption that the newly acquired skills and behaviors are maintained over time 
and are readily adaptable to the demands of new situations. That which patients learn, if properly 
applied, is maintainable after the treatment has ceased and – at least theoretically – for the rest of 
their life. The permanency of what is learned in therapy (i.e., skills, behaviors, etc.) is believed to 
be one of the reasons that the effects of CBT tend to be superior to pharmacological approaches 
at follow-up assessments (Barlow, Gorman, Shear, & Woods, 2000; Cottraux et al., 1995; de 
Beurs, van Dyke, Lange, & van Balkom, 1999).  
Critical examination of the degree to which patients maintain their gains requires long-
term follow-up assessments. Regrettably empirical data on the long lasting (i.e., at least two 
years) effects of treatment are hard to obtain. As a result, knowledge about the longer term effects 
of treatment lag behind our understanding of the immediate efficacy of interventions. The studies 
that do exist provide some support for the long-term efficacy of CBT across numerous disorders 
(Butler, Chapman, Forman, & Beck, 2006), yet some evidence derived across three anxiety 
disorders suggests that effects can begin to recede as soon as one year after treatment (Durham, 
Higgins, Chambers, Swan, & Dow, 2012).  
CBT for Panic Disorder with Agoraphobia (PD/AG) represents an especially important 
test for the long-term effects of CBT given that studies using CBT for this disorder have 
documented some of the highest efficacy rates in the literature and is considered the gold 
standard for this disorder. As such, it may be expected that the stability of gains in the treatment 
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of this disorder should be particularly high. Indeed, evidence from multiple studies suggests that 
treatment gains are maintained through at least 6 months on average (Craske, Brown, & Barlow, 
1991). Fava (1995, 2001) observed high long-term (2 - 14 years) rates, but this group referenced 
only those who successful responded to the original treatment. A recent meta-analysis found that 
the controlled effect size (i.e., in comparison to a wait list) at follow up assessments is 
meaningfully lower than average controlled effect sizes at post-treatment (Sánchez-Meca, Rosa-
Alcázar, Marín-Martínez, & Gómez-Conesa, 2010). Similarly, one of the longest follow-up 
studies followed 189 patients with panic disorder for up to 14 years following several different 
randomized trials and concluded that the short term effects are unrelated to long term outcomes 
(Durham et al., 2005). Similar conclusions were reached in a 15 year follow-up assessment 
following pharmacological treatment of panic disorder (Andersch & Hetta, 2003). To the degree 
these observations are generalizable, the long-term treatment effect of CBT for PD/AG are called 
into question.  
Even less is known about the characteristics of patients’ change beyond effect sizes and 
response rates. That is, the percentage of patients that maintain their gains, improve or worsen 
has not been clearly established. Do these groups differ 6 months and 24 months following 
treatment and is there a subgroup of patients who need more time to respond (during the time 
between 6 and 24 months following treatment)? Likewise, little is known about the percentage of 
patients that report residual symptoms and how these residual symptoms influence global 
functioning. Relatedly, studies show that patients seek additional treatment even after successful 
treatment (Durham et al., 2012). If replicated, this finding raises two additional issues. First, it is 
unclear if these patients are those who have relapsed, or if they sought treatment for reasons other 
than panic symptomatology. Second, it is unclear if opinions of successful treatment outcome 
concur between independent experts and patient’s subjective appraisal. If not, perhaps the 
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disconnect suggested by Durham’s work between successful outcome and additional treatment 
may be explained by the yet untested possibility that patients differ from experts in what 
constitutes a successful outcome. The answers to all of these issues offer important clues about 
the processes that unfold in the time following treatment – the exact period in which our theories 
assume that patients generalize the newly learned material.  
The influence of procedural variations of treatment delivery (e.g., how exposure is 
administered during treatment) on the long-term response is also unknown. It is unclear if 
variance due to treatment variations dissipates over time. It is feasible or even probable that the 
influence of what is learned overshadows any differences in how it was learned. To our 
knowledge, however, no information exists regarding differences in long-term effects that result 
from systematic procedural variations in the delivery of CBT. Instead, previous studies have 
concentrated on how CBT compares to a different treatment package or to an augmented CBT 
with one or more different components added. 
 This study is an extension of a previous study (Gloster et al., 2011) and aimed to examine 
these issues by looking at the durability, pattern, and characteristics of treatment effects from a 
standardized CBT for PD/AG two years following the end of treatment. All patients examined 
were treated with a highly efficacious standardized CBT, as measured at post-treatment and the 
6-month follow up (Gloster et al., 2011). We are therefore able to investigate the long-term 
outcomes using a large sample of patients, all of whom received a standardized efficacious 
treatment. Additionally, all patients in this study were diagnosed with panic disorder and 
agoraphobia. This is important because the presence of agoraphobia has been found to influence 
the outcome of panic disorder (Williams & Falbo, 1996) and most previous studies included 
patients diagnosed with panic disorder with or without agoraphobia. In one exception, patients 
were treated with either a 14-session, 7-session, or group CBT and followed for two years 
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(Marchand, Roberge, Primiano, & Germain, 2009). Significant improvements across all 
treatment modalities and dependent measures were found at post-treatment, one-year and two-
year follow-up, with high end-state functioning achieved by 57% of the patients. Given the 
assumed importance of agoraphobic avoidance, the treatment in this study targeted this factor and 
concentrated heavily on exposure (both interoceptive and in situ in multiple situations), did not 
include explicit components of breathing retraining or logical disputation, and increased anxiety 
in the in situ exposures with interoceptive exercises when patients reported no or insufficient 
anxiety response (Lang et al., 2012). Conceivably, these characteristics supported inhibitory 
learning, which may have facilitated adaptive fear responding (Craske et al., 2008) and this study 
was designed to examine the long-term effects of these factors.  
Importantly, this study also examined a procedural variation of CBT that may inform 
about how long-term treatment gains can be maximized. This approach builds upon other studies 
that examine the global effects of CBT compared to another treatment modalities or treatment 
packages.  Specifically, the treatment examined in this study utilized two procedural variations of 
CBT (i.e., exposure in situ in the presence of the therapist vs. planned in the therapy room), but 
were identical in content (Gloster et al, 2009; Lang et al., 2012).  
Additional strengths of this study that built on previous studies were the large sample size 
that allowed us to examine patterns and issues not amenable to smaller samples and the inclusion 
of outcome variables above and beyond the frequency of panic attacks. This is important because 
evidence has cumulated that panic attacks, panic disorder, and agoraphobia are often independent 
(Craske et al., 2010; Wittchen et al. 2008; Wittchen, Gloster, Beesdo-Baum, Fava, & Craske, 
2010), that agoraphobic avoidance is as important if not more so for long-term outcome (Fava et 
al., 1995), and recent emphasize on how one reacts to the attacks as opposed to the occurrence of 
the attacks themselves (Eifert & Forsyth, 2005).  
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Building on an efficacious treatment and using a relatively large sample, the aim of this 
study was to examine the effects of a standardized CBT for PD/AG two years following the end 
of treatment.  In particular, we examined the durability and pattern of multiple outcomes while 
examining the differential effect of procedural variations, occurrence of additional treatment, 
concordance between the patients’ subjective evaluation of outcome and expert raters, and 
prediction of long-term outcome.  
Method  
Design  
All patients were part of the multicenter Mechanisms of Action in CBT (MAC) RCT for 
Panic Disorder with Agoraphobia (PD/AG) (Gloster et al., 2011). The 24-month follow-up 
assessment (FU-24) was conducted on a subset of four1 of the original eight study centers in the 
MAC Trial. These centers were the largest study cities, thereby allowing maximal utilization of 
resources. All eligible patients from these four centers (n = 198) were contacted and n = 146 
(73.7%) agreed to partake in the FU-24. In this paper, the effects of two treatment groups were 
also examined: (T+) therapists accompanied patients during in situ exposure or (T-) patients were 
prepared for in situ exposure but executed the exposure on their own. The participation rate in the 
FU-24 did not differ between the treatment groups: T+ (81/105, 77.1%) and T- (65/93, 69.9%), 
chi square (1) = 1.34, p > .05. The patients in the study centers selected did not differ from the 
remaining patients in the other centers on any clinical variable at baseline or during the therapy in 
terms of treatment integrity (results available on request).  
 All eligible patients were contacted by phone and invited to the FU-24 follow-up 
interview. Patients who were unreachable were sent letters. In the case that a participant was 
unwilling to participate in the full interview, a short version of the interview was offered that 
captured the most essential information necessary for the main outcomes reported in this study 
                                                           
1 Berlin Adlershofen, Berlin Charite, Dresden, Greifswald 
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(i.e., items assessing the number of panic attacks, avoidance, impairment, overall change 
compared to pre-treatment, whether they obtained additional treatment since the FU-6, and the 
expert rated CGI). Because of this, the sample size varies across analyses. 
Intervention 
 The standardized CBT manual (Lang et al., 2012) was administered in 12 sessions and 
implemented over 6 weeks. The treatment consisted of psychoeducation, individualized behavior 
analysis of the person’s presenting problems, interoceptive exposure, standardized exposure in 
situ (i.e., bus, shopping mall, and forest), individualized exposure in situ, skills to cope with 
anticipatory anxiety, and relapse prevention. Patients received one of two CBT variations that 
were identical except for the way in which the exposure in situ sessions were administered. 
During all exposure sessions, the importance of entering situations without engaging in safety 
behaviors was stressed and practiced. Further details about the therapy and study design have 
already been published (Gloster et al., 2009; Gloster et al., 2011; Lang et al., 2012).   
Therapists 
 Therapists were advanced-level clinical psychology graduate students and post-docs 
experienced in CBT of anxiety disorders. Therapists were only allowed to see patients in the 
study if they completed an extensive three-day training and passed a test consisting of role-plays 
of the critical aspects of the manual. Therapists were trained to see patients in both variants of the 
active treatment. Weekly supervision and videotaping of all sessions was implemented to 
maintain therapy integrity and identify violations of the protocol.  
Assessors 
 Assessors were advanced graduate students in clinical psychology. The assessors were not 
explicitly informed about the patient’s treatment condition (T+ or T-), but it was impossible to 
guarantee that the patient did not reveal details about the treatment such that it could be inferred. 
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Prior to beginning the study, assessors took part in a three-day training, testing, and subsequent 
certification identical to the efficacy study (Gloster et al., 2011). The training included extensive 
practice in the proper administration of the instruments in which all interviews were schooled and 
trained (e.g., role-play, and detailed discussion of common rating scenarios) to the standard of no 
variability for the CGI and only 3 points on the SIGH-A across all exam cases. Most raters (80%) 
were certified as study assessors on the first try, the others passed the exam in form of an 
additional rating after feedback was given on the first. Regular supervision was conducted to 
maintain consistent strategies across assessors and address questions.   
Assessment 
The measures used in this study consist of outcome variables, described first, and those 
assessment measures used in statistical prediction models of outcome, and the instrument used 
for diagnostics.   
Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A; Shear et al., 
2001), is a 14-item interview commonly used to assess the severity of a broad range of anxiety 
symptoms. The SIGH-A has demonstrated high values of inter-rater and test-retest reliability and 
is commonly used in outcome studies.    
Clinical Global Impressions Scale – Severity Subscale (CGI; Guy, 1976). The CGI is a 
clinician-rated scale that measures the overall severity of a disorder, with scores that range 
between 1 (no disorder) and 7 (among the most severely ill patients). The scale queries for 
information across the facets of panic symptoms, anxiety, anticipatory anxiety, avoidance, and 
overall functional level before making the global rating. Scores on the CGI are sensitive to 
change in panic treatment (Barlow et al., 2000; Gloster et al., 2011).  
Mobility Inventory (MI; Chambless, Caputo, Jasin, Gracely, & Williams, 1985). Mobility 
Inventory (MI). The Mobility Inventory is a self-report questionnaire that measures the degree of 
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agoraphobic avoidance across 27 situations, each of which is rated with respect to being in that 
situation alone or accompanied by another person. The mean score of the alone subscale (range 
1-5) are reported. Scores of the MI are highly reliable and sensitive to change (Chambless et al., 
1985, 2011).     
Panic Agoraphobia Scale (PAS; Bandelow, 1999). The PAS is a self-report questionnaire 
that measures the severity of panic attacks, avoidance, anticipatory anxiety, disability, and 
worries about health. Scores on the PAS have been demonstrated to have good reliability and 
sensitivity to change (Bandelow, 1999).  The PAS total score was not originally conceived as a 
primary outcome measure, but is presented to facilitate comparisons with other studies.  
Acceptance and Action Questionnaire II (AAQ- II; Bond et al., 2011), is a 7-item 
unidimensional self-report measure for experiential avoidance and psychological flexibility. 
Items are rated on a 7-point-Likert-scale. High scores reflect more psychological flexibility. The 
AAQ-II explains unique variance in PD/AG patients and was shown to be sensitive to treatment 
effects (Gloster et al., 2011). In this study, the AAQ-II was examined as a predictor of treatment 
outcome.  
Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, and McNally, 1986) is a self-
report instrument assessing anticipatory fear and sensitivity to anxiety symptoms. 16 items are 
rated on a 5-point-Likert-scale. Internal validity is good (Cronbach’s alpha from .82-.92; Alpers 
and Pauli, 2002). Studies have found the ASI to mediate treatment outcome in PD (Smits, 
Powers, Cho, Telch, 2004). In this study, the ASI was examined as a predictor of treatment 
outcome. 
Beck Depression Inventory-2nd Ed. (BDI-II, Beck, Steer, and Brown, 1996; German 
version by Hautzinger, Keller, and Kühner, 2006), a 21-item self-report questionnaire, measures 
depression symptoms according to DSM-IV criteria. Participants rate symptom severity on a 4-
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point-Likert-Scale with respect to the past two weeks. Internal validity is good (Cronbach’s alpha 
from .89-.93.). In this study, the BDI-II was examined as a predictor of treatment outcome. 
Finally, diagnosis was established using the Composite International Diagnostic 
Interview (CIDI) with subsequent clinician review. The standardized computer-administered 
personal CIDI is administered by expert interviewers and systematically assesses all DSM-IV 
disorders. For additional clarification, a clinician then reviewed the diagnoses. The diagnoses 
derived by the CIDI have been demonstrated to be reliable and valid (Essau & Wittchen, 1993; 
Lachner et al, 1988; Reed et al., 1998; Robins et al., 1988; Wittchen 1994; Wittchen & Pfister, 
1997.) 
Statistical Analysis 
 Two possible samples were available for these analyses. These were the full sample of 
patients originally enrolled in the active treatment groups of the study (overall sample; n=301) or 
the subset of patients approached for the FU-24 follow up from the four focal centers (n=198). 
Overall, 146 of the 198 eligible patients (73.7%) from these centers provided data for the FU-24 
(FU-24 subset; n=146). Of note, the number of patients who participated in the FU-24 exceeded 
the participation rate of this group at the 6-month follow-up (136/198 = 68.7%). Analyses were 
run for both the overall sample and FU-24 subset. The sample size varies slightly across analyses 
due to administration of a short version of the interview for patients unwilling to partake in the 
full interview and due to random missing values, and n’s are noted in the tables.   
First, we investigated whether a) those patients from centers who were chosen to 
participate in the FU-24 differed from those patients at the other study centers not approached 
(198 eligible vs. 103 from other centers) and b) actual participants differed from those that 
refused participation in the FU-24 follow up (146 vs. 52 who did not participate). The first 
comparison (a) did not reveal any significant differences (p > .05 in linear regression) at baseline, 
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post-treatment, or FU-6 values of any of the primary outcome measures. The second comparison 
(b) revealed slightly lower HAM-A (25.0 vs. 23.8, F = 4.2 (1, 299), p < .05) and higher CGI 
values (5.2 vs. 5.4, F = 4.7 (1, 299), p < .05) than non-participants at baseline, but interestingly 
not at post-treatment or FU-6.  
The goal of the next set of analyses was to determine the treatment efficacy 24 months 
following treatment. To take into account the full information from all 301 patients at all 
assessments and to address selective dropouts and missing values across treatment groups and 
assessment, we fitted multilevel mixed models (Skrondal & Rabe-Hesketh, 2004). These models 
make much weaker assumptions than conventional complete case and LOCF analysis. In 
particular, they allow for systematic missingness according to the values at other assessments of 
the outcome (Wood, Hillsdon & Carpenter, 2005). To address missingness differentially for 
treatment status (T+ and T-), time (assessments at BL, intermediate, post, FU-6 and FU-24) and 
their combinations, we specified the models saturated for the combined effects of treatment and 
time by using dummy variables for the associated main effects and interactions. This adjusts for 
both the within and between treatment group effects in case of differential missingness (Wood, 
Hillsdon & Carpenter, 2005). We decided to model time as discrete rather than continuous by 
fitting discrete time mixture models. This was done because of the non-equidistant design with 
qualitatively different assessment points offers no one meaningful dimensional metric for time. 
Moreover, we were interested in the exact changes from one assessment to another and this was 
possible with the discrete time mixture models. A random intercept parameter was specified, 
while the other model parameters were specified as fixed and robust standard errors were 
calculated (Royall, 1986). A between group difference was noted at baseline for the variable CGI. 
Between-group differences at the other time points for which a significant difference was found 
(i.e., intermediate, post, and FU-6) were much larger and can only be partially explained by this 
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baseline difference. Beginning with the intermediate assessment, T+ had lower means than T-. 
We concluded therefore that the baseline values do not play a meaningful role after intermediate 
and a negligible role in the main goal of predicting long-term stability as assessed from post-
assessment on. For all other outcomes, randomization worked well and the groups did not differ 
significantly (see Gloster et al., 2011).  Effect sizes were determined as differences in means 
divided by the pooled standard deviation at baseline among all 369 study participants. 
For each outcome we calculated all within group treatment effects as well as predicted 
means (by group and time) from the model coefficients and their 95% confidence interval and p-
values. The observed values were comparable in size and in significance and led to identical 
conclusions. Values from the post-assessment and 6-month follow-up assessment are included in 
order to facilitate comparison across assessment intervals.  
Given differences between those who agreed to participate at FU-24 and those that did not 
with respect to some baseline scores (but not post-treatment or FU-6 ), we conducted a  
sensitivity analysis to assess whether missingness had occurred due to non-considered factors. 
For this, we repeated the entire analysis using only the 146 patients who completed the FU-24 
assessment. Results led to identical conclusions as compared to the full dataset (N = 301) analysis 
(results available upon request).   
Cutoff values used to define response were: SIGH-A: ≥ 50% reduction; CGI: categories 
of “mild”, “borderline”, or “no” disability; MI-alone subscale:  ≤ 1.8; Panic-attacks: 0 panic 
attacks in the past week; and PAS total score: ≥ 50% reduction. Derived from previous studies, 
the cutoffs for Hamilton/ SIGH-A (e.g.,Heldt et al., 2007), CGI (e.g., Barlow, Gorman, Shear, & 
Woods, 2000), and panic attacks (e.g., Pollack, Mangano, Entsuah, Tzanis, & Simon, 2007) have 
been widely used in treatment studies. For the MI, the cutoff value represents a midway point 
between normative and agoraphobic samples: the cutoff value was approximately 1.5 SD’s below 
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the reported means of samples diagnosed with Agoraphobia and 2 SD’s above the mean of a 
normative control group (Chambless et al., 1985). For the PAS, several response criteria have 
been reported in the literature; the 50% reduction is considered conservative (Bandelow, 
Baldwin, Dolberg, Andersen, & Stein). All of these definitions have been consistently used 
within the analyses of the MAC research network (e.g., Gloster et al., 2011; Reif et al., 2013).  
Clinical significance of change was determined using the reliable change index (RCI; 
Jacobson & Truax, 1991). The RCI takes the reliability and standard deviation of the measure 
into account and requires that change on any given measure must exceed that of the RCI.  Cross 
tabulations and associated Fisher’s exact test were calculated to examine the effect of further 
treatment and the concordance between expert opinion and subjective evaluation of outcome. 
Finally, baseline predictors of change between baseline and FU-24 were examined with linear 
regression. For all linear regressions, the robust Huber-White sandwich matrix was used for 
calculation of 95% confidence interval and p-values (Royall, 1986).  
Interactions between the reported need of additional treatment at FU24 and objective need 
(CGI response as rated by therapists) on outcomes were assessed again with linear regressions 
(dimensional outcomes) and logistic regressions (response outcomes), respectively.      
All analyses were conducted with Stata, version 12.1, and the XTMIXED procedure was 
used (Stata Corp, 2012). Significance was set at the .05 level. Global null hypotheses (therapy 
being overall inefficient across all outcomes) where rejected if any of the p-values from 
individual tests was lower than the test level of 0.5 divided by the number of tests (Bonferroni-
correction). In exploratory analyses where groupings of patients resulted in very small cell sizes, 
p-values below .10 are also reported.   
Results  
Two-Year Outcome: Effect Size   
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Collapsing across treatment conditions (T+ and T-), patients reported clear improvement 
with large within group effect sizes at FU-24 compared to pretreatment levels (global test 
rejected, p< .005; d’s range 0.78 to 3.63 across outcomes; see Table 1). Patients in the T+ and T- 
group reported largely similar within group effect sizes across all outcomes. The only significant 
statistical difference between the T+ and T- groups at FU-24 occurred in the level of agoraphobic 
avoidance (MI: difference in d = 0.37, p < .05), where the T+ group reported less avoidance of 
situations than the T- group.  
Two-Year Outcome: Response Rates 
Given that the multi-level data analysis produces only population level estimates, analyses 
of treatment response were necessarily limited to the n = 146 patients who completed the FU-24 
assessment. Based on this group and using LOCF, the number of patients (collapsing T+/ T-) that 
achieved responder status 24 months following treatment was sizable, with differences across 
outcomes: HAM-A: 52.1%; CGI: 85.6%; number of panic attacks: 63.0%, and MI: 67.4%. The 
response rates for the T+ and T- conditions did not differ significantly on any outcome (p > .05), 
though the percentage of responders based on the MI was slightly more than 10% higher in the 
T+ group (73.8%) vs. T- group (59.4%).  
Two-Year Outcome: Clinical Significance 
 We assessed the clinical significance of the observed change using the reliable change 
index (Jacobson & Truax, 1991) on the two broadest outcome measures in our data: PAS and 
CGI. Once again, these analyses were limited to those participants who completed the FU-24 
assessment. Based on the RCI metric, 75.3% (n = 73) of the patients obtained clinically 
significant change in panic and agoraphobia symptoms as measured by the PAS. This percentage 
was not significantly different in the T+ (74.5%, n = 38) and T- (76.1%, n = 35) conditions. With 
respect to global functioning, 67.6% (n = 94) obtained clinically significant change as measured 
Long-Term Follow Up 
 16 
by the CGI. The percentage of patients obtaining clinically significant levels of change was again 
about 10% higher in the T+ condition than the T- condition (72.7%, n = 56 vs. 61.3%, n = 38).  
Change Between 6- and 24-Month Follow-Ups: Effect Size 
Compared to levels measured 6 months following treatment, neither T+ nor T- achieved 
further improvements 18 months later. Although the overall effect sizes and response rates of 
both T+ and T- were excellent, on average the level of symptomatology as measured by effect 
size at FU-24 began to recede towards the post-treatment values and was significant for the 
outcomes HAM-A, MI, and CGI (all p’s < .05). The T+ group reported a significant worsening of 
symptoms between FU-6 and FU-24 on PAS and CGI (p’s < .05), whereas patients of the T- 
condition reported worsening between FU-6 and FU-24 only on the MI (p < .05). 
Stable Gains, Improvement, and Worsening 
In order to determine the stability of change following post-treatment, we calculated the 
percentage of patients who met definitions of positive/ negative status at successive time points 
of post-treatment, FU-6, and FU-24 among those patients who participated in the FU-24 
assessment (see Table 2). The percentage of patients who retained positive status was 
consistently high across all outcome measures and time points (range 69.4% to 96.4%). In 
contrast, the percentage of patients who retained negative status between successive assessments 
varied greatly (12.5% for CGI between FU-6 and FU-24; 73.3% for the MI between FU-6 and 
FU-24). The percentage of patients that improved (negative status followed by positive status) 
was also highly variable across outcomes, with the highest levels of improvement observed for 
the CGI. The percentage of patients who worsened was higher than desired; with values ranging 
from extremely low (3.6% on the MI from Post to FU-6) to clinically disconcerting values 
(30.7% on the HAM-A from FU-6 to FU-24).  
Proportion and Impact of Seeking Additional Treatment 
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Because of previous reports citing that many patients seek additional treatment following 
even successful outcomes (Durham, Higgins, Chambers, Swan & Dow, 2012) the residual 
symptomatology we observed at FU-6 (Gloster et al., 2011), and reports of increased probability 
of seeking additional treatment in the presence of high levels of residual symptomatology – 
especially agoraphobic avoidance (Fava, Zielezny, Savron, & Grandi, 1995), we asked the 
patients if they had “received any additional treatment” since the end of the trial (i.e., FU-6). In 
the context of the interview (i.e., the questions before all dealt with PD/AG and the treatment 
during the study), the question implied but did not specifically ask whether the treatment was for 
the PD/AG. In total, 42 of 112 respondents (37.5%) endorsed having obtained further treatment 
during this 18-month period. This rate did not differ between the T+ and T- conditions (23 of 64, 
35.9% in T+; 19 of 48, 38.6% in T-, chi2(1) =  0.16, p = .693). First we tested the interactions 
between objective response (CGI) and the necessity of additional treatment on dimensional and 
response outcomes at FU24. No evidence was found for any of these interactions (all p’s > .05). 
Second, similar to Durhan et al., we examined the pattern of outcomes grouped by additional 
treatment. As expected, those considered responders by independent expert raters using the CGI 
at FU-24 (Table 3, Columns A and B) had better outcomes than those considered non-responders 
on the CGI (Table 3, Columns C and D). As can also be seen in Table 4, a distinctive pattern 
arose for those patients considered responders from expert raters and those considered non-
responders. For those patients considered responders from the expert raters, those without 
additional treatment generally faired better than those with additional treatment (Table 4, 
Columns A and B). The opposite pattern emerged for those patients considered non-responders 
by the expert raters. For these patients, those that had additional treatment generally had better 
outcomes than those who did not have additional treatment (Table 3, columns C and D). These 
patterns were observed for both dimensional and categorical analyses.  
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Finally, we explored these findings to determine whether those patients who obtained 
additional treatment differed from those that did not in their severity level at FU-6. We predicted 
that those with higher levels of severity would have been more likely to seek treatment. However, 
this could not be substantiated. Although those patients who sought additional treatment had 
consistently higher values across all assessments than those that did not obtain treatment, these 
differences were not significant on any of the five outcome measure (all p’s > .05, estimated 
effect sizes <0.4) at FU-6.   
Concordance Between Expert Raters and Subjective Opinion on Long-Term Outcome 
Next, we asked all patients whether they currently needed additional treatment. Overall, 
40.7% of the patients endorsed this question. In order to determine the concordance between 
subjective appraisal and independent expert assessment, these answers were compared to their 
response status on the CGI. Two forms of disagreement were possible: subjectively indicating the 
need for further treatment despite reaching response status as judged by the expert raters or 
indicating no further need for additional treatment despite being rated as a non-responder by the 
expert raters. The overall concordance between subjective opinion and expert rater was 68%, 
with 32% disagreement. As can be seen in Table 4, most disagreement occurred in column B 
(expert rated as a responder, yet subjective need for additional treatment). It can also be noted, 
that progression from left to right in the table also reveals generally increasing residual 
symptomatology.    
Predictors of Long-Term Change  
 In a final step, we attempted to identify patient variables at baseline that might predict 
change in general functioning (CGI) and panic/agoraphobia symptomatology (PAS) from 
baseline to FU-24. Towards this end we selected variables previously identified within the 
literature. Specifically, we tested the predictive value of sex, age, number of panic attacks, panic 
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symptomatology (PAS), agoraphobic avoidance (MI), clinical global impression (CGI), 
psychological flexibility (AAQ-II), anxiety sensitivity (ASI), and depressive symptoms (BDI-II). 
When collapsing across treatment conditions (T+/ T-), no tested predictor emerged as significant 
for either outcome variable. Next, we tested the interactions between baseline predictor and 
treatment group on outcome status. No evidence was found for any of these interactions (all p’s > 
.05).  
Discussion 
This study examined the two-year outcome of manualized CBT for PD/AG in a large 
multi-center randomized trial. Overall, excellent outcomes were observed compared to the level 
of symptomatology with which patients presented prior to treatment. The effect sizes two years 
following treatment were somewhat lower than 6 months following treatment, but generally as 
good as or better than the levels immediately following treatment (i.e., post-treatment). In 
contrast, the rates of responders were equivalent to or greater than the rates 6 months following 
treatment. The change observed was also clinically meaningful, with between 2/3 (CGI) and 3/4 
(PAS) of patients reporting change that exceeded critical values on the reliable change index. 
Thus, on average, the efficacious effects of this treatment observed at post-treatment and 6-month 
follow-up were maintained two years following the end of treatment.  
The observed effect sizes, response rates, and percentage of patients with reliable change 
were consistent with and sometimes better than previous two-year outcome studies for panic 
disorder with and without agoraphobia (e.g., Craske, Brown, & Barlow, 1991; Fava et al., 2001; 
Marchand, Roberge, Primiano, & Germain, 2009). This is notable given some of the 
characteristics of the treatment: targeting of avoidance and concentration on exposure (both 
interoceptive and in situ in multiple situations), temporal compression (two appointments per 
week), and exclusion of the explicit components of breathing retraining or logical disputation. 
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Thus, the elements included in the treatment appear to have a salient long-term effect for most 
patients, conceivably by increasing inhibitory learning (Craske et al., 2008).  
Despite the overall positive results observed in our data two years following treatment, 
changes between FU-6 and FU-24 suggested that outcomes ceased to continue to improve and in 
some outcomes showed marginal worsening. Presently it is unclear if the observed receding 
suggests a type of regression to the mean, whether the values would continue to deteriorate with 
more time, or whether the values would stabilize at or around these values. Differences patterns 
between the T+ and T- during this period are likely a function of the absolute value of outcomes 
at the FU-6 assessment. In other words, the T+ condition had somewhat better outcomes than T- 
at FU-6 and therefore had more room to regress to the norm. The notable exception to this is the 
MI, where the T+ group maintained their level of avoidance whereas the T- statistically 
worsened. This difference is potentially of importance, as the degree of agoraphobic avoidance 
has been the most consistently observed difference between the two groups (Gloster et al., 2011) 
and thus suggests one of the mechanisms by which the two treatment groups differ. Such a 
position is supported by previous studies that point to the importance of reducing agoraphobic 
avoidance (Fava, 1995). Until this can be further empirically verified, however, this hypothesis 
remains speculative.  
Having witnessed the marginal reduction of treatment gains – however small – we felt it 
important to examine and document the stability/ fluctuation of outcome status across assessment 
time points beyond means and effect sizes. Towards this aim, we examined whether patients met 
criteria for response for two consecutive time periods: post treatment to FU-6 and FU-6 to FU-24. 
Examining participants in this way revealed several important patterns. First, stability (i.e., 
retained positive/ negative status) was much more common than fluctuation (i.e., improved or 
worsened), with at least 2/3 of the sample in the stable categories for most outcome measures (MI 
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rates were even higher). Second, among those patients who fluctuated in status, the percentage 
that improved was always greater than the percentage that worsened. This held true across each 
time period and outcome measure. Taken together, these analyses suggest that most respond 
positively, maintain their positive status, and if transition occurs it is usually in a positive 
direction. However, the percentage that worsened or retained negative status is higher than 
desired. Indeed, we agree with recent calls to specifically address this group of treatment non-
responders and treatment-resistant patients with targeted research (Pollack et al., 2008).  
With the aim of further understanding residual symptomatology, we examined how 
responder status on global functioning (CGI) interacted with whether or not the patients obtained 
further treatment since the FU-6. Overall, one-third of the patients obtained additional treatment. 
We failed to find a significant difference between those who obtained additional treatment and 
those that did not with respect to their levels of symptomatology at FU-6. Whereas we cannot say 
whether the additional treatment specifically addressed PD/AG, we do assume that these patients 
did not judge themselves to be free of mental distress or else they would not have sought out 
additional treatment. About half of the patients were considered responders by expert raters 
(CGI) and did not need additional treatment. These patients continued to fair better than all other 
groups. Durham et al (2012) referred to these patients as having obtained a “sustained recovery” 
group. The rates of sustained recovery in this study were higher than those reported by Durham et 
al. for patients followed for up to 14 years (approximately 50% vs. 38%) A second group of 
patients, consisting of about one-third of this sample, needed and obtained additional treatment 
and this likely contributed to these patients being judged as responders by the expert raters. The 
rates of patients considered non-responders by the expert raters was much smaller, and in some 
cases so small that the statistics should be considered with caution. Within this group, slightly 
less than half received additional treatment, yet remained a non-responder. Durham labeled this 
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group “treatment resistant”. The rates of treatment resistant patients were lower in this study than 
in patients followed for up to 14 years (approximately 5% vs. 19%, Durham et al., 2012). It 
remains an open question how the rates observed in this study would continue to look better than 
the values reported by Durham 12 years into the future (suggesting a differentiation of treatment 
effects) or recede (indicating a loss of potency over increasing time periods). These findings are 
inconsistent with Durham et al. who found that those who obtained additional treatment were 
worse off. Similar to Durham et al., however, we observed meaningful levels of residual 
symptomatology in all groups except the responders who did not obtain additional treatment. 
Once again, however, it should be noted that the group of patients categorized as non-responders 
was small.  
 We also examined at FU-24 whether outcome as assessed by expert raters and subjective 
appraisal of outcome were in agreement. Overall, the concordance between expert raters and 
subjective judgments were good. The mean levels of residual symptomatology increased 
consistently across the four groups. Of particular interest to us were the disagreements between 
expert raters and subjective report. Most disagreement came from those patients categorized as 
responders by the expert raters, yet the patients indicated the need for additional treatment. The 
other disagreement (non-responders who indicated they didn’t need additional treatment) was 
very small and should be interpreted with caution. If replicable, however, the interesting question 
arises as to why some patients feel they need more therapy while others do not, despite 
comparable levels of symptomatology (i.e, groups B and C did not significantly differ from each 
other). It is further unclear what leads the group of patients to feel they need additional treatment 
although the expert raters judged otherwise. Remarkably, this group accounted for approximately 
one-third of the sample.  
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Finally, we examined predictors of long-term change (BL-FU-24). The predictors we 
tested established from previous research did not prove to be robust. Baseline severity level of 
PD/AG symptomatology, the most consistent baseline predictor from previous studies, was not 
significant in this study. These results surprised us to some degree, especially given that this data 
set was one of the larger to examine these relationships and thus is presumed to have adequate 
statistical power. Methodologically, variance may have been restricted to a greater extent in this 
study than previous studies due to the highly standardized conditions and the fact that the overall 
response to treatment was very positive. Thus, baseline levels of these variables may not be 
nearly as relevant in predicting outcome two years later as the processes that occurred during 
specific phases of treatment (Cammin-Nowak et. al, 2013; Emmerich et al., in prep; Gloster, et 
al., in press).   
 This study is limited in several important ways. First, not all patients from the original 
study sample were approached for the FU-24 follow-up assessment. Although statistical controls 
failed to find differences and multi-level analyses utilized to model the complete sample, this 
remains a source of potential bias. Second, of the eligible patients not all were willing to 
participate in the FU-24 follow-up assessment. Statistical tests found a difference between the 
patients who agreed and declined participation on some variables at baseline, but not at post-
treatment or FU-6. Nevertheless, its effect on unobserved variables important for the treatment 
can not be excluded. Third, with the goal of maximizing participation rates, a short form of the 
interview and assessment was available for participants that did not wish to complete a full 
assessment battery. Although this did indeed increase overall participation rates, it 
simultaneously led to fewer responses on some questionnaires. Given the difficulty securing the 
participation of patients so long after treatment – especially when residual problems are present – 
this cost was deemed acceptable. Finally, as is common in a psychological study of this sort, it 
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could not be completely ruled out that the patients revealed details of their treatment condition to 
the assessor. This potential treat to the blinding should be considered when interpreting the 
results.  
Despite these limitations, it can be concluded that on average patients maintained 
clinically meaningful effects two years following treatment across multiple outcome measures. 
The effects were somewhat lower than effects observed 6 months following treatment. Our 
examination of procedural variation revealed that, overall, both treatment variations had positive 
outcomes. The only difference between the two treatment variations at FU-24 was in the degree 
of agoraphobic avoidance, which was lower in the T+ group. The greater improvement in 
agoraphobic avoidance in the T+ condition is consistent with our previous findings (Gloster et al., 
2011). Avoidance behavior was one of the main targets of this treatment and residual levels of 
avoidance have been found to be a risk factor for relapse (Fava, Zielezny, Savron, & Grandi, 
1995). As such, we cautiously conclude that this difference, while small, may be of clinical 
importance. 
Enthusiasm is tempered, however, by what appears to be approximately one third of the 
sample with meaningful residual difficulties. These rates are largely consistent with rates 
observed in previous studies.  We present detailed analysis of these residual issues seldom 
presented in previous long-term studies, with the goal of refining the discussion in the field. To 
borrow a term from a similar phenomenon in the treatment of depression, we wish to actively 
work towards improving the “hidden third” (Schlaepfer et al., 2012). Yes, the overall picture is 
good. Yet, additional treatment options are likely needed when our current treatments fail to work 
for these patients.  
In conclusion, patients generally obtained meaningful and lasting change through two 
years following treatment. The most salient difference between these variations was a continued 
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greater reduction in agoraphobic avoidance, which was targeted as the central aim of new 
learning within this therapy and is considered by some to be a central if not the central maintain 
factor (Fava, Zielezny, Savron, & Grandi, 1995; Powers et al., 2004). This bodes well for the 
permanency presumption of change underlying CBT. Whereas the percentage of patients who 
met criteria for positive response two years following treatment was good across outcomes, there 
is still significant room for improvement. Clinical scientists should strive to develop interventions 
for the subgroup of patients that do not adequately respond and ultimately work towards 
developing interventions that will achieve even better long-term outcomes.  
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Table 1. Model-based (mixed effects models) predicted means and effect sizes for main outcomes for T+ (n=163) & T-(n=138)
Outcome Assessment N Mean N Mean N Mean ES p-value ES p-value ES p-value ES p-value
HAM-A Total Pre 301 24.5 163 24.7 138 24.2 Ref. Ref. Ref. Ref.
Intermediate 301 24.5 / / / / / / / / / / / /
Post 301 12.8 163 12.8 138 12.9 -2.21 0.000 -2.26 0.000 -2.16 0.000 0.11 0.527
FU 6 months 301 10.4 163 10.2 138 10.6 -2.69 0.000 -2.77 0.000 -2.59 0.000 0.18 0.350
FU 24 months 301 13.1 163 13.3 138 12.8 -2.17 0.000 -2.17 0.000 -2.18 0.000 -0.01 0.981
FU 24 - Post 301 0.2 163 0.5 138 -0.1 0.04 0.818 0.09 0.740 -0.02 0.903 -0.12 0.732
FU 24 - FU6 301 2.7 163 3.1 138 2.2 0.52 0.003 0.60 0.026 0.41 0.053 -0.18 0.591
CGI Total Pre 301 5.3 163 5.4 138 5.2 Ref. Ref. Ref. Ref.
Intermediate 301 4.8 163 4.8 138 4.9 -0.64 0.000 -0.81 0.000 -0.43 0.000 0.38 0.013
Post 301 3.7 163 3.6 138 3.8 -2.32 0.000 -2.59 0.000 -2.00 0.000 0.59 0.003
FU 6 months 301 2.8 163 2.7 138 2.9 -3.63 0.000 -3.91 0.000 -3.29 0.000 0.61 0.013
FU 24 months 301 3.1 163 3.1 138 3.1 -3.09 0.000 -3.25 0.000 -2.90 0.000 0.35 0.290
FU 24 - Post 301 -0.5 163 -0.5 138 -0.6 -0.77 0.000 -0.66 0.005 -0.90 0.000 -0.24 0.468
FU 24 - FU6 301 0.4 163 0.5 138 0.3 0.54 0.002 0.66 0.006 0.40 0.123 -0.26 0.454
# panic attacks Pre 301 2.6 163 2.7 138 2.4 Ref. Ref. Ref. Ref.
Intermediate 301 2.0 163 2.2 138 1.8 -0.24 0.000 -0.22 0.004 -0.26 0.001 -0.04 0.691
Post 301 1.1 163 1.2 138 1.0 -0.62 0.000 -0.66 0.000 -0.58 0.000 0.07 0.553
FU 6 months 301 0.5 163 0.4 138 0.5 -0.89 0.000 -0.99 0.000 -0.79 0.000 0.20 0.110
FU 24 months 301 0.7 163 0.9 138 0.5 -0.78 0.000 -0.77 0.000 -0.78 0.000 0.00 0.987
FU 24 - Post 301 -0.4 163 -0.3 138 -0.5 -0.15 0.024 -0.12 0.242 -0.19 0.023 -0.07 0.575
FU 24 - FU6 301 0.3 163 0.5 138 0.0 0.12 0.066 0.21 0.031 0.01 0.906 -0.20 0.108
MI-Unaccompagnied Pre 301 3.0 163 3.0 138 2.9 Ref. Ref. Ref. Ref.
Intermediate 301 2.8 163 2.8 138 2.7 -0.27 0.000 -0.29 0.000 -0.24 0.000 0.05 0.503
Post 301 2.0 163 1.9 138 2.1 -1.20 0.000 -1.38 0.000 -0.98 0.000 0.40 0.000
FU 6 months 301 1.5 163 1.4 138 1.6 -1.77 0.000 -1.89 0.000 -1.61 0.000 0.28 0.042
FU 24 months 301 1.6 163 1.5 138 1.7 -1.61 0.000 -1.77 0.000 -1.40 0.000 0.37 0.039
FU 24 - Post 301 -0.3 163 -0.3 138 -0.4 -0.41 0.000 -0.39 0.002 -0.42 0.000 -0.03 0.840
FU 24 - FU6 301 0.1 163 0.1 138 0.2 0.16 0.036 0.12 0.291 0.21 0.030 0.09 0.527
PAS Total Pre 301 27.8 163 28.4 138 27.1 Ref. Ref. Ref. Ref.
Intermediate 301 23.1 163 23.5 138 22.6 -0.48 0.000 -0.50 0.000 -0.46 0.000 0.04 0.692
Post 301 14.5 163 14.4 138 14.6 -1.37 0.000 -1.43 0.000 -1.29 0.000 0.14 0.231
FU 6 months 301 8.9 163 8.4 138 9.6 -1.94 0.000 -2.05 0.000 -1.80 0.000 0.25 0.063
FU 24 months 301 11.3 163 11.7 138 10.9 -1.69 0.000 -1.71 0.000 -1.67 0.000 0.04 0.839
FU 24 - Post 301 -3.2 163 -2.7 138 -3.7 -0.32 0.001 -0.28 0.065 -0.38 0.003 -0.10 0.609
FU 24 - FU6 301 2.4 163 3.3 138 1.3 0.25 0.015 0.34 0.019 0.14 0.328 -0.20 0.311
Note: / = Not assessed at this time point; * Difference of within effect sizes
Treated Effect sizes within treatedT+ T- Effect sizes within T+ Effect sizes within T- Effect sizes betweeen T+ and T-
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Table 2: Status Across Successive Measurement Points
Post - FU6 FU6 - FU24 Post - FU6 FU6 - FU24 Post - FU6 FU6 - FU24 Post - FU6 FU6 - FU24
Outcome % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
HAM-A 84.5% (49) 69.4% (43) 15.5% (9) 30.7% (19) 49.1% (27) 61.5% (16) 50.9% (28) 38.5% (10)
CGI 89.7% (52) 89.8% (79) 10.3% (6) 10.2% (9) 35.0% (21) 12.5% (3) 65.0% (39) 87.5% (21)
PAS 89.3% (50) 80.7% (50) 10.7% (6) 19.4% (12) 42.1% (24) 36.4% (8) 57.9% (33) 63.6% (14)
MI 96.4% (54) 87.5% (56) 03.6% (2) 12.5% (8) 38.5% (15) 73.3% (11) 61.5% (24) 26.7% (4)
Note. Status defined according to response definitions: HAM-A (50% reduction from BL); CGI ("mild" or less); PAS (50% reduction from BL); MI (≤ 1.8)
Retained Negative Status ImprovedRetained Positive Status Worsened
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Table 3: Proportion Seeking Additional Treatment Following Post-treatment and Impact 
 
 
 
  
 Expert Rated as Responder at FU-24 (CGI) Expert Rated as Non-Responder at FU-24 (CGI) 
Outcome (A)                                                            
No Additional Tx                     
(B)                                               
Received Additional Tx                  
(C)                                                             
No Additional Tx                      
(D)                                                   
Received Additional 
Tx                       
Significant Contrasts
Dimensional  N Mean SD N Mean SD N Mean SD N Mean SD  
HAM-A (mean) 54 10.8 9.0 34 12.6 9.2 8 24.3 11.2 5 22.4 14.7 A,B < C   
PAS 52 8.6 8.9 26 14.0 10.7 6 26.2 13.1 5 15.8 5.8 A < B,C,D; B,D* <C 
P. Attacks 58 0.5 1.1 32 0.4 0.9 7 4.0 2.4 5 0.8 1.3 A,B,D < C  
MI 51 1.4 0.6 29 1.7 0.8 6 2.2 1.1 5 2.2 0.5 A<B*,C*,D; B<D* 
              
Response Rate Ntot N % Ntot N % Ntot N % Ntot N %  
HAM-A 54 34 63.0 34 22 64.7 8 0 0.0 5 2 40.0 A,B > C 
PAS 52 41 78.8 26 15 57.7 6 1 16.7 5 4 80.0 A > B*, C; D* > C 
P. Attacks 58 42 72.4 32 24 75.0 7 1 14.3 5 3 60.0 A,B > C 
MI 51 43 84.3 29 18 62.1 6 3 50.0 5 1 20.0 A > B,C*,D 
Note: n's vary across questionnaires due to missing values; significant contrasts were listed if p < .05; given the small cell sizes of some 
comparisons trends (*) were also listed when p < .10 
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Table 4: Concordance Between Subjective Definition and Expert Rating of Treatment Outcome 
 
 
 
 Expert Rated as Responder at FU-24 (CGI) Expert Rated as Non-Responder at FU-24 (CGI)  
Outcome (A)                                                           
Don't Need Additional 
Tx                     
(B)                                            
Need Additional Tx                  
(C)                                             
Don't Need Additional 
Tx                      
(D)                                           
Need Additional Tx                       
Significant
Contrasts 
Dimensional N Mean SD N Mean SD N Mean SD N Mean SD  
HAM-A 
(mean) 
59 9.6 8.6 31 15.2 8.6 2 12.0 4.3 11 25.7 11.9 A< B; A,B,C < D 
PAS 56 8.0 7.9 26 14.9 11.4 3 17.3 7.6 10 24.6 15.2 A< B,C,D; B < D* 
P. Attacks 64 0.4 0.8 31 0.7 1.4 3 1.3 1.5 11 3.3 2.8 A,B,C* < D 
MI 57 1.5 0.6 27 1.6 0.8 3 2.1 1.0 10 2.2 0.9 A,B < D 
              
Response 
Rate 
Ntot N % Ntot N % Ntot N % Ntot N %  
HAM-A 59 41 69.5 31 15 48.4 2 1 50.0 11 1 9.1 A > B*,D; B > D 
PAS 56 45 80.4 26 15 57.7 3 2 66.7 10 4 40.0 A > B*,D 
P. Attacks 64 49 76.6 31 21 67.7 3 1 33.3 11 3 27.3 A,B > D 
MI 57 43 75.4 27 22 81.5 3 1 33.3 10 4 40.0 A*,B > D 
Note: n's vary across questionnaires due to missing values; significant contrasts were listed if p < .05; given the small cell sizes of some 
comparisons trends (*) were also listed when p < .10 
 
